Amphastar Pharmaceuticals to Present at the Raymond James 2021 Institutional Healthcare Conference
February 26 2021 - 06:01AM
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that
Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and
HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations,
and Jacob Liawatidewi, Executive V.P. Corporate Administration
Center and Sales & Marketing, will participate in an
Analyst-Moderated fireside chat at the Raymond James 2021
Institutional Healthcare Conference on Tuesday, March 2, 2021 at
1:20 pm Eastern time.
This presentation will be made available webcast
and may be accessed by visiting Amphastar Pharmaceuticals' website
at http://ir.amphastar.com. This webcast will be available for 90
days following the presentation.
About Amphastar:
Amphastar is a specialty pharmaceutical company
that focuses primarily on developing, manufacturing, marketing, and
selling technically-challenging generic and proprietary injectable,
inhalation, and intranasal products. Additionally, the Company
sells insulin active pharmaceutical ingredient products. Most of
the Company’s finished products are used in hospital or urgent care
clinical settings and are primarily contracted and distributed
through group purchasing organizations and drug wholesalers. More
information is available at the Company’s website at
www.amphastar.com.
The Amphastar Pharmaceuticals’ logo and other
trademarks or service marks of Amphastar
Pharmaceuticals, Inc., including, but not limited to
Primatene®, Amphadase® and Cortrosyn®, are the property of
Amphastar Pharmaceuticals, Inc.
Forward Looking Statements
All statements in this press release and in the
conference call referenced above that are not historical are
forward-looking statements, including, among other things,
statements relating to the Company’s expectations regarding future
financial performance, backlog, sales and marketing of its
products, market size and growth, the timing of FDA filings or
approvals, including the DMFs of ANP, the timing of product
launches, acquisitions and other matters related to its pipeline of
product candidates, its share buyback program and other future
events, such as the impact of the COVID-19 pandemic and related
responses of business and governments to the pandemic on our
operations and personnel, and on commercial activity and demand
across our business operations and results of operations. These
statements are not historical facts but rather are based on
Amphastar’s historical performance and its current expectations,
estimates, and projections regarding Amphastar’s business,
operations, and other similar or related factors. Words such as
“may,” “might,” “will,” “could,” “would,” “should,” “anticipate,”
“predict,” “potential,” “continue,” “expect,” “intend,” “plan,”
“project,” “believe,” “estimate,” and other similar or related
expressions are used to identify these forward-looking statements,
although not all forward-looking statements contain these words.
You should not place undue reliance on forward-looking statements
because they involve known and unknown risks, uncertainties, and
assumptions that are difficult or impossible to predict and, in
some cases, beyond Amphastar’s control. Actual results may differ
materially from those in the forward-looking statements as a result
of a number of factors, including those described in Amphastar’s
filings with the Securities and Exchange Commission, including in
the Annual Report on Form 10-K for the year ended December 31,
2019, filed with the SEC on March 16, 2020. In particular, the
extent of COVID-19’s impact on our business will depend on several
factors, including the severity, duration and extent of the
pandemic, as well as actions taken by governments, businesses, and
consumers in response to the pandemic, all of which continue to
evolve and remain uncertain at this time. You can locate these
reports through the Company’s website at http://ir.amphastar.com
and on the SEC’s website at www.sec.gov. The forward-looking
statements in this release speak only as of the date of the
release. Amphastar undertakes no obligation to revise or update
information or any forward-looking statements in this press release
or the conference call referenced above to reflect events or
circumstances in the future, even if new information becomes
available or if subsequent events cause Amphastar’s expectations to
change.
Contact: Bill Peters Chief Financial Officer (909)
476-3416
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From Mar 2023 to Mar 2024